| 应用 |
BIBF1120 is a potent kinase inhibitor found to affect VEGF, PDGF, and FGF receptors. |
| 产品介绍 |
Nintedanib (BIBF 1120)是一种有效的三重血管激酶抑制剂，对VEGFR1/2/3， FGFR1/2/3和PDGFRα/β均有抑制作用，其IC50分别为34 nM/13 nM/13 nM， 69 nM/37 nM/108 nM和59 nM/65 nM。 |
| 备注 |
Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50 of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM. Phase 2. |
| 生化机理 |
BIBF1120 inhibits PDGFR kinase activity of PDGFR alpha and PDGFR beta types with IC50 values of 59 and 65 nM, respectively. In addition, BIBF1120 suppresses the FGFR subtypes with IC50 of 60, 37 and 108 nM for FGFR1, FGFR2, and FGFR3, respectively. BIBF1120 binds to the ATP-binding site in the cleft between the amino and carboxy terminal lobes of the kinase domain. |
| 别名 |
BIBF 1120;尼达尼布;Vargatef; Intedanib;Nintedanib; BIBF1120; BIBF-1120 |
